Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24618033 | 0.85 | GRIN1 (0.40) | ALBFOLH1MEN1KMT2APOLB | |
| SCHEMBL24617914 | 0.85 | GRIN1 (0.40) | ALBFOLH1MEN1KMT2APOLB | |
| SCHEMBL24622267 | 0.85 | GRIN1 (0.40) | ALBFOLH1MEN1KMT2APOLB | |
| SCHEMBL24618034 | 0.85 | GRIN1 (0.40) | ALBFOLH1MEN1KMT2APOLB | |
| SCHEMBL24617923 | 0.85 | GRIN1 (0.40) | ALBFOLH1MEN1KMT2APOLB | |
| SCHEMBL24617920 | 0.85 | GRIN1 (0.40) | ALBFOLH1MEN1KMT2APOLB | |
| SCHEMBL24618010 | 0.85 | FOLH1 (0.43) | ALBFOLH1PARP14 | |
| SCHEMBL24618028 | 0.85 | FOLH1 (0.43) | ALBFOLH1PARP14 | |
| SCHEMBL24618012 | 0.85 | NR2F2 (0.41) | ALBFOLH1MEN1KMT2APOLB | |
| SCHEMBL26225557 | 0.84 | ALB (0.39) | ALBFOLH1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331801-A1 | IL-2R-BETA-GAMMA BINDING COMPOUNDS | MEDIKINE, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11718654-B2 | IL-2R-βγ binding compounds | MEDIKINE, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210253670-A1 | IL-7R-ALPHA-GAMMA BINDING COMPOUNDS | BLUEBIRD VENTURES I, L.P. | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331801-A1 | IL-2R-BETA-GAMMA BINDING COMPOUNDS | IL2RA, IL2, IL15RA | ALB 1363/4885FOLH1 2443/4885MEN1 4744/4885 |
| US-20210253670-A1 | IL-7R-ALPHA-GAMMA BINDING COMPOUNDS | IL2RA, IL2, IL6ST | ALB 1918/4885FOLH1 3432/4885MEN1 4155/4885 |
| US-11718654-B2 | IL-2R-βγ binding compounds | IL2RA, IL2, IL1RN | ALB 2282/4885FOLH1 2905/4885MEN1 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.